Welcome to our dedicated page for IQVIA HOLDINGS SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IQVIA HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IQVIA HOLDINGS's regulatory disclosures and financial reporting.
LEONARD JOHN M reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director John M. Leonard reported receiving an equity award of 1,571 shares of common stock on April 23, 2026. The shares were granted as compensation for his role as a non-employee director and are fully vested upon grant, with no purchase price paid. Following this award, Leonard directly holds 16,946 shares of IQVIA common stock.
GOGGINS COLLEEN A reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Colleen A. Goggins received an award of 1,571 shares of common stock on April 23, 2026. The shares were granted as compensation for Non-Employee Directors and are fully vested upon grant, bringing her direct holdings to 14,453 shares.
Fasano Jim reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Jim Fasano received a grant of 1,571 deferred shares, each linked to one share of common stock. These deferred shares settle when he ceases to be a director, upon a change in control of the company, or upon his death. Following this award, he holds 5,845 deferred shares in total.
IQVIA HOLDINGS INC. director John G. Danhakl reported an indirect acquisition of 1,571 shares of common stock on an award that was fully vested upon grant for Non-Employee Directors. These shares are held in the Danhakl Revocable Family Trust.
Following the award, the trust holds 30,612 shares of IQVIA common stock, and a related LLC controlled by the trust holds an additional 1,275 shares. The filing reflects compensation-related grants and indirect holdings, not open-market purchases or sales.
Burt Carol reported acquisition or exercise transactions in this Form 4 filing.
IQVIA Holdings Inc. director Carol Burt received an equity award of 1,571 shares of common stock as a non-employee director. The shares were fully vested upon grant and are held indirectly in the Carol Burt Hilliard Revocable Trust, bringing her indirect holdings to 7,533 shares.
IQVIA Holdings Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved the new 2026 Incentive and Stock Award Plan, which replaces the 2017 plan and supports a wide range of equity awards tied to performance measures such as revenue, adjusted EBITDA and relative total stockholder return.
As of the February 23, 2026 record date, 167,866,339 common shares were outstanding and entitled to vote. All nominated directors were elected. The advisory vote on 2025 executive compensation passed with 118,398,355 votes for and 29,398,856 against. Shareholders approved the 2026 Plan with 96,987,612 votes for and 51,006,455 against, and ratified PricewaterhouseCoopers LLP as auditor with 140,865,227 votes for. A stockholder proposal to separate the Chairman and CEO roles did not pass, receiving 36,717,802 votes for and 111,154,252 against.
IQVIA Holdings Inc. — The Vanguard Group filed Amendment No. 11 to a Schedule 13G/A reporting beneficial ownership of 0 shares of Common Stock, representing 0% of the class. The filing states that on January 12, 2026 Vanguard completed an internal realignment and will report certain subsidiaries separately in reliance on SEC Release No. 34-39538. The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
IQVIA Holdings Inc. is asking stockholders to vote at its 2026 annual meeting on five items, including electing directors, an advisory say‑on‑pay vote, ratifying PricewaterhouseCoopers as auditor, approving a new 2026 Incentive and Stock Award Plan, and a stockholder proposal opposed by the Board.
The company highlights 2025 revenue of $16.3 billion, Adjusted EBITDA of $3.8 billion, and Free Cash Flow of $2.1 billion, along with $1.8 billion in strategic acquisitions and $1.2 billion returned via repurchases of about 7.4 million shares.
IQVIA emphasizes AI leadership, record clinical development backlog of $32.7 billion, strong governance features such as a fully independent Board (other than the CEO), majority voting for directors, proxy access, special meeting rights, robust clawback policies, and an executive pay program heavily weighted to performance-based equity.
Haas Bernd reported disposition transactions in a Form 4 filing for IQV. The filing lists transactions totaling 20 shares at a weighted average price of $166.94 per share. Following the reported transactions, holdings were 24,394 shares.